Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- LabCorp to Acquire Genzyme Genetics for US$925 Mil. in Cash
September 27, 2010
- Fingolimod Approved in Russia: Novartis
September 27, 2010
- E Keppra to Expand Market for Anti-epileptic Agents: Otsuka, UCB
September 27, 2010
- 5-Aminolevulinic Acid HCl Designated as Orphan Drug
September 27, 2010
- Shionogi Licenses 2 SLIT Tablets from Stallergenes
September 20, 2010
- Ancaron Approved for Additional Indication Based on Data from Public Domain
September 20, 2010
- ViiV to Continue Its Commitment to HIV Area: President Iriyama
September 20, 2010
- Multaq Recommended as First-Line Option for AF in ESC GL
September 20, 2010
- Bayer to Embark on Esthetic Dermatology Business
September 20, 2010
- Earlier Access to Unapproved Drugs Proposed at Chuikyo
September 20, 2010
- Overall Price Settlement Rate at 28.1% as of the End of June
September 20, 2010
- Pfizer to Undertake Development of Injectable Metronidazole
September 20, 2010
- JMHA to Jointly Purchase Drugs
September 20, 2010
- Takara Bio Licenses Nucleic Acid Refining Reagent from Macherey-Nagel
September 20, 2010
- Eisai Launches Glufast in China
September 20, 2010
- Rivaroxaban Non-Inferior to Standard Therapy: Bayer
September 20, 2010
- Sawai Prepares for Biosimilars Business
September 20, 2010
- Apixaban More Effective than Aspirin in AF: BMS/Pfizer
September 20, 2010
- Sandoz to Expand Range of Target Doctors for Somatropin Biosimilars
September 20, 2010
- JSNM to Promote Use of PET Drugs for Drug Discovery
September 20, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…